-Spectral joins leading Japanese medical centres in presenting data on
clinical utility of EAA(TM) diagnostic-
TORONTO, Feb. 28 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it will present new findings demonstrating the clinical utility of its EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin, at the 12th Annual Critical Care for Endotoxemia congress. The conference takes place in Fukuoka, Japan from February 28th-29th, 2008 and focuses on the role of endotoxemia in sepsis in critically ill patients. The Company and a number of leading medical centres in Japan including the Tokyo Medical Clinic, Osaka City General Hospital and Iwate Medical University will each present findings using data collected with Spectral's EAA(TM) product that highlight the clinical utility of the diagnostic.
"More than one-third of the presentations being given at this important conference use data collected with our EAA(TM) and highlight the value of our product. With Japan being one of the leading nations that emphasize the importance of endotoxin and its role in sepsis, our unique EAA(TM) diagnostic plays a prominent role in patient care," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "This data supports our expanded distribution relationship with Toray, which commenced last quarter. Toray's therapeutic column, Toraymyxin, is highly effective in removing endotoxin from the bloodstream and together with EAA(TM) has been recognized in Japan as a valuable combination for the diagnosis, treatment and monitoring of patients with endotoxemia."
Debra Foster, Director of Spectral's Sepsis Program, will present Friday February 29th at 8:30am Japanese Standard Time. Following the conference, the findings presented will be published in the Japan Journal for Critical Care for Endotoxemia.
About Spectral Diagnostics
Spectral is a develo
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved